The decision on the "optimal" human pluripotent stem cell

Stem Cells Translational Medicine

Volumn 3, Issue 5, 2014, Pages 553-559

  Rosner, Margit ^a   Schipany, Katharina ^a   Hengstschläger, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER;

AMNIOCENTESIS; AMNIOTIC FLUID CELL; ARTICLE; CARCINOGENICITY; CELL CLONING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL TYPE; CHROMOSOME ABERRATION; DISEASE MODEL; EMBRYONIC STEM CELL; EPIGENETICS; FERTILIZATION IN VITRO; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN PLURIPOTENT STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; TERATOCARCINOMA; TERATOMA;

AMNIOTIC FLUID; BIOETHICAL ISSUES; EMBRYONIC STEM CELLS; GENOMIC INSTABILITY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84899672289     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0194     Document Type: Article

References (23)

1. Zhu H, Lensch MW, Cahan P et al. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 2011; 12:266-275.
2. Mathe G, Jammet H, Pendic B et al. Transfusions et greffes de moelle osseuse homologue chez des humains irradiés à haute dose accidentellement [in French]. Rev Fr Etud Clin Biol 1959; 4:226-238.
3. Ilic D, Polak JM. Stem cell based therapy-Where are we going?. Lancet 2012;379:877-878.
4. Rosner M, Hengstschläger M. Amniotic fluid stem cells and fetal cell microchimerism. Trends Mol Med 2013;19:271-272.
5. Tachibana M, Amato P, Sparman M et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013;153: 1228-1238.
6. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011;11: 268-277.
7. Rosner M, Hengstschläger M. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:1764-1765.
8. Daley GQ, Lensch MW, Jaenisch R et al. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 2009; 4:200-201; author reply 202.
9. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;3:595-605.
10. Ellis J, Bruneau BG, Keller G et al. Alternative induced pluripotent stem cell characterization criteria for in vitro applications. Cell Stem Cell 2009;4:198-199; author reply 202.
11. Müller FJ, Goldmann J, Löser P et al. A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell 2010;6:412-414.
12. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147.
13. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
14. Takahashi K, Tanabe K, OhnukiMet al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
15. Prusa AR, Marton E, RosnerMet al. Oct-4-expressing cells in human amniotic fluid: A new source for stem cell research? HumReprod 2003;18:1489-1493.
16. De Coppi P, Bartsch G Jr., Siddiqui MM et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007;25: 100-106.
17. Valli A, Rosner M, Fuchs C et al. Embryoid body formation of human amniotic fluid stem cells depends on mTOR. Oncogene 2010;29: 966-977.
18. RosnerM, Siegel N, Fuchs C et al. Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells. Nat Protoc 2010;5:1081-1095.
19. Moschidou D, Mukherjee S, Blundell MP et al. Valproic acid confers functional pluripotency to human amniotic fluid stem cells in a transgene-free approach. Mol Ther 2012;20: 1953-1967.
20. Rosner M, Dolznig H, Schipany K et al. Human amniotic fluid stem cells as a model for functional studies of genes involved in human genetic diseases or oncogenesis. Oncotarget 2011;2:705-712.
21. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011;13: 497-505.
22. Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol 2010;28:989-990.
23. Fink DW Jr. FDA regulation of stem cell-based products. Science 2009;324:1662-1663.